Application of a clinical decision support tool for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicenter study

被引：0
|
作者：
Kim, K. [1 ]
Hong, S. W. [1 ]
Park, J. H. [1 ]
Hwang, S. W. [1 ,2 ]
Park, S. H. [1 ,2 ]
Yang, D. H. [1 ]
Byeon, J. S. [1 ]
Myung, S. J. [1 ]
Yang, S. K. [1 ,2 ]
Yoo, J. H. [3 ]
Boo, S. J. [4 ]
Kim, E. S. [5 ]
Lee, J. [6 ]
Kim, K. O. [7 ]
Ye, B. D. [1 ,2 ]
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Ctr Inflammatory Bowel Dis, Seoul, South Korea
[3] CHA Univ, CHA Bundang Med Ctr, Dept Internal Med, Sch Med, Seongnam, South Korea
[4] Jeju Natl Univ, Dept Internal Med, Sch Med, Jeju, South Korea
[5] Korea Univ, Anam Hosp, Dept Gastroenterol, Seoul, South Korea
[6] Chosun Univ, Dept Internal Med, Coll Med, Gwangju, South Korea
[7] Yeungnam Univ, Dept Internal Med, Coll Med, Daegu, South Korea
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P560
引用
收藏
页码：I503 / I504
页数：2
相关论文
共 50 条
  • [31] Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease
    Plevris, Nikolas
    Jenkinson, Philip W.
    Chuah, Cher S.
    Lyons, Mathew
    Merchant, Lynne M.
    Pattenden, Rebecca J.
    Arnott, Ian D.
    Jones, Gareth R.
    Lees, Charlie W.
    FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 117 - 123
  • [32] Transition to Subcutaneous Infliximab vs Vedolizumab in Inflammatory Bowel Disease: A Prospective Multicenter Study
    Principi, Mariabeatrice
    Brescia, Irene Vita
    Stasi, Elisa
    Mazzuoli, Silvia
    D'Uggento, Angela Maria
    Equatore, Elena
    Lacavalla, Ilaria
    Di Leo, Alfredo
    DIGESTIVE DISEASES AND SCIENCES, 2024, : 4458 - 4466
  • [33] VEDOLIZUMAB EXPERIENCE IN CHILDREN AND ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE: A MULTICENTER OBSERVATIONAL STUDY (VOLCANO)
    Hajjat, Temara
    Mosha, Maua H.
    Suppa, Carmine
    Markowitz, James
    Whaley, Kaitlin G.
    Rosen, Michael J.
    Shukla-Udawatta, Monica
    Boyle, Brendan M.
    Hunter, Gabriele
    Perez, Maria E.
    Hyams, Jeffrey S.
    GASTROENTEROLOGY, 2019, 156 (06) : S840 - S841
  • [34] Risk factors and clinical characteristics of Clostridium difficile colonization and infection in patients with inflammatory bowel disease exposed to Vedolizumab: a multicenter retrospective study
    Li, Qing
    Song, Xiaomei
    Su, Peizhu
    Lv, Xiaoping
    Liu, Xinyu
    Chen, Xuemin
    Tang, Jian
    Gao, Xiang
    Chao, Kang
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2025, 18
  • [35] CLINICAL CHARACTERISTICS, MEDICATION UTILIZATION, AND CLINICAL OUTCOMES OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND HEART FAILURE: A MULTICENTER NETWORK STUDY
    Tanner, Samuel
    Perez, Jaime
    Martin, Scott A.
    Kelly, Hannah M.
    Alkhayyat, Motasem
    Abou Saleh, Mohannad
    Cooper, Gregory S.
    Sinh, Preetika
    Al-Kindi, Sadeer
    Falck-Ytter, Yngve T.
    Regueiro, Miguel D.
    Katz, Jeffry
    Cominelli, Fabio
    Mansoor, Emad
    GASTROENTEROLOGY, 2022, 162 (07) : S436 - S436
  • [36] Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study
    Baumgart, D. C.
    Bokemeyer, B.
    Drabik, A.
    Stallmach, A.
    Schreiber, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (10) : 1090 - 1102
  • [37] Vedolizumab Drug Levels During Maintenance Therapy in Inflammatory Bowel Disease Patients
    Koduru, Pramoda
    Morrill, Amanda
    Abraham, Bincy
    INFLAMMATORY BOWEL DISEASES, 2017, 23 : S63 - S64
  • [38] Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study
    Albshesh, A.
    Kucha, P.
    Pugliese, D.
    Amiot, A.
    Mahajna, H.
    Eder, P.
    Savarino, E. V.
    Vavricka, S.
    Castiglione, F.
    Imperatore, N.
    Krznaric, Z.
    Abitbol, C. M.
    Hen, O.
    Zaborowska, M.
    Carbonnel, F.
    Cuccia, G.
    Lorenzon, G.
    Zittan, E.
    Zagorowicz, E.
    Maniero, D.
    Ben-Horin, S.
    Kopylov, U.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i2105 - i2106
  • [39] Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab
    Jessica R. Allegretti
    Edward L. Barnes
    Betsey Stevens
    Margaret Storm
    Ashwin Ananthakrishnan
    Vijay Yajnik
    Joshua Korzenik
    Digestive Diseases and Sciences, 2017, 62 : 1590 - 1596
  • [40] Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease
    Parikh, Asit
    Fox, Irving
    Leach, Timothy
    Xu, Jing
    Scholz, Catherine
    Patella, Michael
    Feagan, Brian G.
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (08) : 1691 - 1699
12345